Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 1Genitourinary 1

Conditions

Hearing Loss 1Head and Neck Neoplasms 1Carcinoma, Squamous Cell 1Advanced Renal Cell Carcinoma (RCC) 1

Interventions

Specimen Handling 288Magnetic Resonance Spectroscopy 238pembrolizumab 228Carboplatin 187Cisplatin 153Biopsy 151Cyclophosphamide 144Paclitaxel 133Nivolumab 123Gemcitabine 113Bevacizumab 106Radiotherapy 96Dexamethasone 86Pemetrexed 83fludarabine 78Fluorouracil 76Doxorubicin 76Docetaxel 76atezolizumab 73Radiation 72Leucovorin 70Rituximab 68Oxaliplatin 66venetoclax 61durvalumab 61Prednisone 61Vincristine 56Cetuximab 56Lenalidomide 55Etoposide 54

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Atorvastatin × 30 days × Clear all
NCT04915183 2026-06-05

Atorvastatin to Reduce Cisplatin-Induced Hearing Loss Among Individuals With Head and Neck Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
224 enrolled
Head & Neck

Carcinoma, Squamous Cell, Head and Neck Neoplasms, Hearing Loss

NCT07630363 2026-06-05

PTC-Guided Atorvastatin Plus Axitinib and Toripalimab in Advanced RCC

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 1/2 Not yet recruiting
40 enrolled
Genitourinary

Advanced Renal Cell Carcinoma (RCC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡